Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 10, 2014, Pages 1618-1625

  Oran, Betul ^a   Kongtim, Piyanuch ^a   Popat, Uday ^a   de Lima, Marcos ^a   Jabbour, Elias ^a   Lu, Xinyan ^a   Chen, Julien ^a   Rondon, Gabriella ^a   Kebriaei, Partow ^a   Ahmed, Sairah ^a   Andersson, Borje ^a   Alousi, Amin ^a   Ciurea, Stefan ^a   Shpall, Elizabeth ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cytoreduction; Hypomethylating agents; Monosomal karyotype; Stem cell transplantation

Indexed keywords

BUSULFAN; FERRITIN; FLUDARABINE; MELPHALAN; METHOTREXATE; TACROLIMUS; ANTINEOPLASTIC ANTIMETABOLITE; MYELOABLATIVE AGENT;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOMONOCYTIC LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; CYTOREDUCTIVE SURGERY; DISEASE COURSE; DONOR; EVENT FREE SURVIVAL; FERRITIN BLOOD LEVEL; FOLLOW UP; GRAFT VERSUS HOST REACTION; HIGH RISK POPULATION; HISTOLOGY; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MAJOR CLINICAL STUDY; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; RETROSPECTIVE STUDY; TREATMENT OUTCOME; TREATMENT RESPONSE; AGE; ALLOTRANSPLANTATION; BLOOD; CHROMOSOME ANALYSIS; DNA METHYLATION; DRUG EFFECTS; FEMALE; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TEST; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MONOSOMY; MORTALITY; MYELODYSPLASTIC SYNDROMES; PATHOLOGY; PROCEDURES; PROGNOSIS; RECURRENT DISEASE; RISK FACTOR; SURVIVAL; UNRELATED DONORS;

AGE FACTORS; ANTIMETABOLITES, ANTINEOPLASTIC; CYTOGENETIC ANALYSIS; DNA METHYLATION; FEMALE; FERRITINS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MALE; MIDDLE AGED; MONOSOMY; MYELOABLATIVE AGONISTS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84912573970     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.06.022     Document Type: Article

References (28)

1. Hofmann W.K., Koeffler H.P. Myelodysplastic syndrome. Annu Rev Med 2005, 56:1-16.
2. Appelbaum F.R., Storb R., Ramberg R.E., et al. Treatment of preleukemic syndromes with marrow transplantation. Blood 1987, 69:92-96.
3. Sierra J., Perez W.S., Rozman C., et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood 2002, 100:1997-2004.
4. Castro-Malaspina H., Harris R.E., Gajewski J., et al. Unrelated donor marrow transplantation for myelodysplastic syndromes: outcome analysis in 510 transplants facilitated by the National Marrow Donor Program. Blood 2001, 99:1943-1951.
5. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
6. Schanz J., Steidl C., Fonatsch C., et al. Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in theinternational prognostic scoring system. JClin Oncol 2011, 29:1963-1970.
7. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. JClin Oncol 2008, 26:4791-4797.
8. Greenberg P.L., Tuechler H., Schanz J., et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012, 120:2454-2465.
9. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
10. Weisdorf D., Spellman S., Haagenson M., et al. Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. Biol Blood Marrow Transplant 2008, 14:748-758.
11. Giralt S., Ballen K., Rizzo D., et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009, 15:367-369.
12. Patnaik M.M., Hanson C.A., Hodnefield J.M., et al. Monosomal karyotype in myelodysplastic syndromes, with or without monosomy 7 or 5, is prognostically worse than an otherwise complex karyotype. Leukemia 2011, 25:266-270.
13. Belli C.B., Bengio R., Aranguren P.N., et al. Partial and total monosomal karyotypes in myelodysplastic syndromes: comparative prognostic relevance among 421 patients. Am J Hematol 2011, 86:540-545.
14. Deeg H.J., Scott B.L., Fang M., et al. Five-group cytogenetic risk classification, monosomal karyotype, and outcome after hematopoietic cell transplantation for MDS or acute leukemia evolving from MDS. Blood 2012, 120:1398-1408.
15. Della Porta M.G., Alessandrino E.P., Bacigalupo A., et al. Predictive factors for the outcome of allogeneic transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R). Blood 2014, 123:2333-2342.
16. Valcarcel D., Adema V., Sole F., et al. Complex, not monosomal, karyotype is the cytogenetic marker of poorest prognosis in patients with primary myelodysplastic syndrome. JClin Oncol 2013, 31:916-922.
17. Saber W., Opie S., Rizzo J.D., et al. Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 2012, 119:3908-3916.
18. Brunstein C.G., Gutman J.A., Weisdorf D.J., et al. Allogeneic hematopoietic cell transplantation for hematologic malignancy: relative risks and benefits of double umbilical cord blood. Blood 2010, 116:4693-4699.
19. Horowitz M.M. Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients?. Best Pract Res Clin Haematol 2012, 25:483-486.
20. Damaj G., Duhamel A., Robin M., et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Societe Francaise de Greffe de Moelle et de Therapie-Cellulaire and the Groupe-Francophone des Myelodysplasies. JClin Oncol 2012, 30:4533-4540.
21. Field T., Perkins J., Huang Y., et al. 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010, 45:255-260.
22. Kim D.Y., Lee J.H., Park Y.H., et al. Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant 2012, 47:374-379.
23. De Padua Silva L., de Lima M., Kantarjian H., et al. Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 2009, 43:839-843.
24. de Witte T., Hagemeijer A., Suciu S., et al. Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. Haematologica 2010, 95:1754-1761.
25. Scott B.L., Storer B., Loken M.R., et al. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome. Biol Blood Marrow Transplant 2005, 11:65-73.
26. Gerds A.T., Gooley T.A., Estey E.H., et al. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Biol Blood Marrow Transplant 2012, 18:1211-1218.
27. Andersson B.S., Valdez B.C., de Lima M., et al. Clofarabine+/- fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant 2011, 17:893-900.
28. de Lima M., Giralt S., Thall P.F., et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 2010, 116:5420-5431.